Trial Profile
SAFETY AND TOLERABILITY STUDY OF SLIT AMIKACIN 500 MG ONCE DAILY FOR 14 DAYS BY INHALATION IN CYSTIC FIBROSIS STUDY SUBJECTS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Amikacin (Primary)
- Indications Cystic fibrosis; Pseudomonal infections
- Focus Adverse reactions
- 03 Apr 2022 Status changed from recruiting to completed.
- 18 May 2011 New trial record